Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Imatinib

Drug and asset intelligence for Imatinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Recent signals(1)

ClinicalJuly 3, 2026

Study on Genetic Aberrations in Wild Type GIST Patients in Taiwan

A pilot study aims to evaluate genetic aberrations in wild type GIST patients in Taiwan using an oncopanel test.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Imatinib

Monitor results from the oncopanel tests and any subsequent treatment developments based on genetic findings.

July 3, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Gastrointestinal Stromal Tumor →
Oncology →
Oncology · Gastrointestinal Stromal Tumor →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.